The Endocannabinoid System as an Emerging Target of Pharmacotherapy

By P. Pacher, S. Batkai, George Kunos. Pharmacological Reviews, 2006

2,081 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Pharmacology, Plant Science

View Paper: https://www.semanticscholar.org/paper/6941200d14b7890c67da4088ffbd0b40aeb393bb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. U. Kumar
2. Shenglong Zou
3. Hui-Chen Lu
4. L. Parker
5. K. Mackie
6. B. Cravatt
7. R. Mechoulam
8. V. Di Marzo

In Pharmacology

1. U. Kumar
2. Shenglong Zou
3. B. Cravatt
4. Jonathan Z. Long
5. V. Di Marzo
6. Hui-Chen Lu
7. L. Parker
8. K. Mackie

In Plant Science

1. U. Kumar
2. Shenglong Zou
3. Gea Guerriero
4. Christelle M Andre
5. J. Hausman
6. V. Di Marzo

Citations in the corpus

• Cannabis sativa: The Plant of the Thousand and One Molecules (2016, background): “The sum of the THC and CBD fractions (without reporting the distinct amounts of each of them) in hemp stem wood and bark extractives was 2 and 1%, respectively, which represented 0.003 and 0.0005% of the total fiber content.”
• An introduction to the endogenous cannabinoid system (2015, background): “Despite anandamide and 2-AG both containing arachidonic acid, their routes of synthesis and degradation in vivo are almost completely distinct and are mediated by different enzymes (39).”
• Targeting the endocannabinoid system: to enhance or reduce? (2008, background): “Intriguingly, for the same pathological condition, there are often reports of both positive and negative changes, and of both protective and worsening effects of endocannabinoid receptor activation in the tissues and organs involved in the disorde”
• The endocannabinoid system and the brain. (2013, background): “There is emerging evidence that lipid endocannabinoid signaling through CB2 receptors may represent an example/part of such a protective system” (Pacher & Mechoulam 2011, p. 194).”
• Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system (2010, positive): “Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl) piperidine-1-carboxylate (JZL184) enhances retrograde endocannabinoid signaling.”
• Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System (2018, background): “Indeed, the CB1R and the endocannabinoid system are largely involved in various aspects of central neural activities and disorders, including appetite, learning and memory, anxiety, depression, schizophrenia, stroke, multiple sclerosis, neurodegeneration, epilepsy, and addiction [3,9,126,127].”
• ESPEN guidelines on nutrition in cancer patients. (2017, background): “Investigation of these substances has led to the emergence of pharmacotherapy targets [229] which include, among others, those related to appetite, an issue in cancer patients.”